股票代码：300289 股票简称：利德曼 上市地点：深圳证券交易所 北京利德曼生化股份有限公司 重大资产购买报告书（草案）摘要 | 项目 | 交易对方 | | --- | --- | | | 上海百家汇投资管理有限公司、海南先声百家 | | 重大资产购买 | 汇科技发展有限公司、南京百佳瑞企业管理咨 | | | 询合伙企业（有限合伙） | 独立财务顾问 财务顾问 二〇二五年十一月 重大资产购买报告书（草案） 声 明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、上市公司声明 本公司保证《北京利德曼生化股份有限公司重大资产购买报告书（草案）》 及其他申请文件内容的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏。如因本次重组的信息披露存在虚假记载、误导性陈述或者重大遗漏， 给投资者造成损失的，本公司将依法承担个别及连带的法律责任。 二、交易对方声明 本次重组的交易对方已就在本次交易过程中所提供资料的真实、准确、完 整情况出具以下承诺： 1、本公司/本企业保证为本次交易所提供资料和信息均真实、准确、完整， 保证不存在虚假记载、误导性陈述或重大遗漏，并对所提供资料和信息的真实 性、 ...

董事会关于本次交易履行法定程序的完备性、合规性及提交的法律文 件的有效性的说明 北京利德曼生化股份有限公司 （二）公司按照相关规定，对本次重大资产重组的交易进程备忘录及内幕信息知 情人进行了登记，并对内幕信息知情人买卖公司股票的情况进行查询，并将有关材料 向深圳证券交易所进行报备。 （三）公司独立董事认真审核了本次交易相关文件，对本次交易相关事项进行了 审议，同意将本次交易相关事项提交董事会审议。 （四）公司按照相关法律、法规和规范性文件的要求编制了《北京利德曼生化股 份有限公司重大资产购买报告书（草案）》及有关文件。 （五）2025年11月13日，公司第六届董事会第七次会议、第六届监事会第七次会 议审议通过了本次交易的相关议案。 （六）2025年11月13日，公司与交易对方签署了《股权收购协议》及《业绩承诺 及补偿协议》。 北京利德曼生化股份有限公司（以下简称"公司"或"上市公司"）拟以支付现 金的方式购买上海百家汇投资管理有限公司（以下简称"上海百家汇"）、海南先声 百家汇科技发展有限公司（以下简称"海南百家汇"）、南京百佳瑞企业管理咨询合 伙企业（有限合伙）（以下简称"南京百佳瑞"，与上海百家汇、海南百 ...

北京利德曼生化股份有限公司 董事会关于本次交易符合《上市公司重大资产重组管理办法》第十一条及 不适用第四十三条、第四十四条规定的说明 北京利德曼生化股份有限公司（以下简称"公司"或"上市公司"）拟以支付现 金的方式购买上海百家汇投资管理有限公司（以下简称"上海百家汇"）、海南先声 百家汇科技发展有限公司（以下简称"海南百家汇"）、南京百佳瑞企业管理咨询合 伙企业（有限合伙）（以下简称"南京百佳瑞"）合计持有的北京先声祥瑞生物制品 股份有限公司（以下简称"先声祥瑞"或"标的公司"）267,526,000 股股份（占先声 祥瑞已发行股份的 70%）（以下简称"本次交易"）。 公司董事会对本次交易符合《重组管理办法》第十一条及不适用第四十三条、第 四十四条的规定进行了审慎分析，董事会认为： 本次交易的标的公司从事业务不属于高能耗、高污染的行业。标的公司在经营过 程中严格遵守国家环境保护规定，符合环保要求。报告期内，标的公司不存在因违反 国家及地方有关环境保护的法律法规而受到有关环保主管部门重大行政处罚的情形。 本次交易符合有关环境保护的法律和行政法规的规定。 3、本次交易符合有关土地管理方面的法律和行政法规的规定 ...

股票代码：300289 股票简称：利德曼 上市地点：深圳证券交易所 财务顾问 二〇二五年十一月 重大资产购买报告书（草案） 北京利德曼生化股份有限公司 重大资产购买报告书（草案） | 项目 | 交易对方 | | --- | --- | | | 上海百家汇投资管理有限公司、海南先声百家 | | 重大资产购买 | 汇科技发展有限公司、南京百佳瑞企业管理咨 | | | 询合伙企业（有限合伙） | 独立财务顾问 本次重组的交易对方已就在本次交易过程中所提供资料的真实、准确、完 整情况出具以下承诺： 1、本公司/本企业保证为本次交易所提供资料和信息均真实、准确、完整， 保证不存在虚假记载、误导性陈述或重大遗漏，并对所提供资料和信息的真实 性、准确性和完整性承担个别和连带的法律责任。 2、本公司/本企业保证向上市公司及为本次交易提供专业服务的中介机构 提交全部所需文件及相关资料，同时承诺所提供纸质版和电子版文件及相关资 料均完整、真实、可靠，有关副本材料或者复印件与原件一致，文件上所有签 字与印章皆真实、有效，复印件与原件相符；所有文件的签名、印章均是真实 的，并已履行该等签署和盖章所需的法定程序、获得合法授权；不存在任 ...

北京利德曼生化股份有限公司（以下简称"公司"或"上市公司"）拟以支付现 金的方式购买上海百家汇投资管理有限公司（以下简称"上海百家汇"）、海南先声 百家汇科技发展有限公司（以下简称"海南百家汇"）、南京百佳瑞企业管理咨询合 伙企业（有限合伙）（以下简称"南京百佳瑞"，与上海百家汇、海南百家汇以下合 称"交易对方"）合计持有的北京先声祥瑞生物制品股份有限公司（以下简称"先声 祥瑞"）267,526,000股股份（占先声祥瑞已发行股份的70%）（以下简称"本次交 易"）。 上市公司董事会就本次交易是否构成《上市公司重大资产重组管理办法》第十三 条规定的重组上市情形，进行核查并发表如下意见： 本次交易的交易方式为支付现金购买资产，不涉及向交易对方发行股份，不会导 致公司的股权结构发生变化，不会导致上市公司的控股股东、实际控制人变更。因此， 本次交易不构成《上市公司重大资产重组管理办法》第十三条规定的重组上市。 特此说明。 （以下无正文） 北京利德曼生化股份有限公司董事会 北京利德曼生化股份有限公司 董事会关于本次交易不构成《上市公司重大资产重组管理办法》第十三条 规定的重组上市情形的说明 2025 年 11 月 1 ...

Core Insights - The medical device sector experienced a rise of 0.57% on November 12, with Tianyi Medical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Device Sector Performance - Tianyi Medical (301097) closed at 65.30, up 11.34% with a trading volume of 46,500 and a transaction value of 294 million [1] - Jimin Health (603222) closed at 11.33, up 10.00% with a trading volume of 729,500 and a transaction value of 797 million [1] - Zhongyuan Xiehe (600645) closed at 28.61, up 10.00% with a trading volume of 311,400 and a transaction value of 857 million [1] - Other notable gainers include Danah Biotechnology (920009) up 9.99%, Lideman (300289) up 9.89%, and Yipeng Medical (300753) up 8.21% [1] Capital Flow Analysis - The medical device sector saw a net inflow of 739 million from institutional investors, while retail investors experienced a net outflow of 923 million [2][3] - Jimin Health had a net inflow of 205 million from institutional investors, but a net outflow of 138 million from retail investors [3] - Zhongyuan Xiehe also saw a net inflow of 194 million from institutional investors, with a significant net outflow of 932 million from retail investors [3]

Group 1 - A-share market opened lower but rose, with the medical device sector showing active performance, as the medical device ETF increased by 0.65% and has seen net inflows for 11 consecutive trading days, totaling over 90 million yuan [1] - The brain-computer interface field in China has made significant progress, with Shanghai Ladder Medical Technology's "implantable wireless brain-computer interface system" entering the special review process by the National Medical Products Administration, marking the first invasive brain-computer interface product to enter this "green channel" [1] - Guosen Securities noted that the rebound in equipment procurement in the first half of 2025 is gradually being recognized in Q3, with significant year-on-year improvements in revenue and net profit for the medical device sector in Q3 2025, driven by domestic economic recovery and equipment update tenders [1] Group 2 - The long-term positive trend in the medical device sector remains unchanged, with the medical device ETF (562600) providing a convenient way to invest in this area, tracking the CSI All-Share Medical Device Index which includes 100 representative listed companies in core medical fields [2] - Investors can also consider the 华夏中证全指医疗器械ETF发起式联接A (021250) and 华夏中证全指医疗器械ETF发起式联接C (021251) for easy allocation in the medical device sector [2]

Core Viewpoint - The medical device sector experienced a slight decline of 0.31% on November 6, with Danaher Biomedical leading the losses, while the overall market indices showed gains, with the Shanghai Composite Index up by 0.97% and the Shenzhen Component Index up by 1.73% [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4007.76, increasing by 0.97% [1]. - The Shenzhen Component Index closed at 13452.42, increasing by 1.73% [1]. - The medical device sector saw a net outflow of 638 million yuan from major funds, while retail investors contributed a net inflow of 446 million yuan [2][3]. Group 2: Individual Stock Performance - Hualan Co., Ltd. (301093) saw a significant increase of 8.53%, closing at 44.00 yuan with a trading volume of 67,500 shares and a transaction value of 293 million yuan [1]. - Danaher Biomedical (920009) led the declines with a drop of 4.69%, closing at 83.50 yuan and a trading volume of 24,900 shares, resulting in a transaction value of 206 million yuan [2]. - Other notable gainers included Furuida (300049) with a 4.32% increase and a closing price of 74.56 yuan, and Kangzhong Medical (688607) with a 3.04% increase, closing at 29.81 yuan [1][2]. Group 3: Fund Flow Analysis - Major funds showed a net outflow in several stocks, including Furuida with a net outflow of 23.99 million yuan, while retail investors showed a net inflow of 25.27 million yuan [3]. - Dongfulong (300171) experienced a net inflow of 21.17 million yuan from major funds, indicating positive sentiment towards the stock [3]. - The overall trend indicates a mixed sentiment in the medical device sector, with some stocks attracting retail interest despite the overall outflow from major funds [2][3].

Core Insights - The company, Lideman, reported that as of October 31, 2025, the number of shareholders reached 33,688 [2] Company Summary - Lideman's shareholder count is projected to be 33,688 by the end of October 2025 [2]

Core Viewpoint - Lidman has experienced a significant stock price increase of 51.84% year-to-date, despite a recent decline in the last five and twenty trading days [2]. Company Overview - Beijing Lidman Biochemical Co., Ltd. was established on November 5, 1997, and listed on February 16, 2012. The company specializes in in vitro diagnostic reagents (biochemical, immunological, molecular), diagnostic instruments, and biochemical raw materials [2]. - The revenue composition of Lidman includes: in vitro diagnostic reagents 67.84%, diagnostic instruments 14.17%, other (property leasing/management, etc.) 13.21%, and biochemical raw materials 4.78% [2]. Stock Performance - As of October 31, Lidman's stock price was 7.44 CNY per share, with a market capitalization of 4.047 billion CNY. The stock saw a trading volume of 47.6122 million CNY and a turnover rate of 1.19% [1]. - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) four times this year, with the most recent appearance on August 8 [2]. Financial Performance - For the period from January to September 2025, Lidman reported a revenue of 252 million CNY, a year-on-year decrease of 10.49%. The net profit attributable to the parent company was -7.1348 million CNY, a decrease of 765.83% year-on-year [2]. - The company has distributed a total of 143 million CNY in dividends since its A-share listing, with 5.4401 million CNY distributed in the last three years [3]. Shareholder Information - As of October 20, 2025, Lidman had 33,600 shareholders, an increase of 1.96% from the previous period. The average circulating shares per person decreased by 1.92% to 16,170 shares [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 2.0113 million shares, while Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund (004685) and Huaxia CSI 500 Index Enhanced A (007994) have exited the top ten [3].